Knockout Mouse Project Would Target 500 New Lines Annually
This article was originally published in The Pink Sheet Daily
Executive Summary
The advantages of such an effort would include “efficient production with reduced costs; uniform use of knockout methods, allowing for more comparability between knockout mice; and ready access to mice, their derivatives and data,” the group behind the proposed project predicts.
You may also be interested in...
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
Nebivolol Approval Could Come In Mid-2007, Forest Says
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.
Akorn’s Inapsine Set To Return To U.S. Market In June
The company has inked a hospital supply contract for the anesthetic droperidol.